• Zealand Pharma announced positive Phase 1 multiple-dose results for ZP9830, its Kv1.3 ion channel blocker, on October 19, 2026.
• The trial enrolled 32 healthy participants, with four weeks of treatment and safety follow-up through day 41.
• All treatment-emergent adverse events with ZP9830 were mild and non-serious; no dose-limiting safety findings emerged.
• Pharmacokinetic results support longer-duration studies; a Phase 1b trial with efficacy endpoints in plaque psoriasis is underway.
• A Phase 2 trial in an additional autoimmune disease is planned to start in the first half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zealand Pharma A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610190100PRIMZONEFULLFEED1001278536) on October 19, 2026, and is solely responsible for the information contained therein.